针对经选择患者组全部患者的治疗推荐
第一选择
环磷酰胺
:
1-2 mg/kg/天,口服,每天 1 次,连服 6-12 个月;500-1000 mg/平方米体表面积,静脉注射,每月 1 次,连续 6-12 个月
或
或
环孢素
:
3-4 mg/kg/日,口服,分 2 次给药,根据患者反应逐渐增加剂量,每日最大剂量不超过 5 mg/kg
更多
环孢素
不同品牌之间的生物利用度存在差异。
或
他罗利姆。
:
0.1-0.2 mg/kg/天,口服,分 2 次给药
或
吗替麦考酚酯
:
1-1.5 g,口服,每天 2 次
皮质类固醇和二线制剂难治时使用。
这些人更可能患有某种程度上已经稳定的严重症状。
每种治疗可单独使用或联合口服皮质类固醇使用。
与其他类型的炎性肌病相比,包涵体肌病中的疗效不佳。
环磷酰胺被用于难治性多发性肌炎与皮肌炎,尤其与血管炎、ILD 及延髓或呼吸肌损伤的疾病有关时。[59]Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985;12:1140-1148.http://www.ncbi.nlm.nih.gov/pubmed/4093921?tool=bestpractice.com[72]Leroy JP, Drosos AA, Yiannopoulos DI, et al. Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome. Arthritis Rheum. 1990;33:1579-1581.http://www.ncbi.nlm.nih.gov/pubmed/2222539?tool=bestpractice.com[64]Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics. 2008;5:548-557.http://www.ncbi.nlm.nih.gov/pubmed/19019306?tool=bestpractice.com[73]Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129-137.http://www.ncbi.nlm.nih.gov/pubmed/20125096?tool=bestpractice.com
苯丁酸氮芥的使用已在少数难治性皮肌炎研究中取得一些成功。[55]Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003;16:569-575.http://www.ncbi.nlm.nih.gov/pubmed/14501840?tool=bestpractice.com[74]Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36:319-324.http://www.ncbi.nlm.nih.gov/pubmed/8452575?tool=bestpractice.com
环孢素已显示其在多发性肌炎或皮肌炎中的功效。[55]Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003;16:569-575.http://www.ncbi.nlm.nih.gov/pubmed/14501840?tool=bestpractice.com[75]Cordeiro AC, Isenberg DA. Treatment of inflammatory myopathies. Postgrad Med J. 2006;82:417-424.http://www.ncbi.nlm.nih.gov/pubmed/16822917?tool=bestpractice.com治疗开始后 2 至 6 周内可能会注意到情况有所改善,且大多数患者可以减少或停止使用皮质类固醇。[55]Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003;16:569-575.http://www.ncbi.nlm.nih.gov/pubmed/14501840?tool=bestpractice.com[76]Correia O, Polonia J, Nunes JP, et al. Severe acute form of adult dermatomyositis treated with cyclosporine. Int J Dermatol. 1992;31:517-519.http://www.ncbi.nlm.nih.gov/pubmed/1500250?tool=bestpractice.com[77]Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1:1063-1066.http://www.ncbi.nlm.nih.gov/pubmed/2566009?tool=bestpractice.com[78]Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27:2855-2859.http://www.ncbi.nlm.nih.gov/pubmed/11128676?tool=bestpractice.com[73]Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129-137.http://www.ncbi.nlm.nih.gov/pubmed/20125096?tool=bestpractice.com[65]Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24:457-462http://www.ncbi.nlm.nih.gov/pubmed/21799409?tool=bestpractice.com在难治性或复发性皮肌炎或多发性肌炎中,单独或联合 IVIG 和皮质类固醇使用环孢素可能有效。[79]Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61:37-41.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753869/pdf/v061p00037.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/11779756?tool=bestpractice.com
在少数病例中发现,他克莫司和麦考酚酯均有效。[80]Schneider C, Gold R, Schafers M, et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve. 2002;25:286-288.http://www.ncbi.nlm.nih.gov/pubmed/11870700?tool=bestpractice.com[81]Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762-1763.http://www.ncbi.nlm.nih.gov/pubmed/10347992?tool=bestpractice.com[82]Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27:1542-1545.http://www.ncbi.nlm.nih.gov/pubmed/10852287?tool=bestpractice.com病例研究发现,他罗利姆的临床改善是多种多样的,可能在 3 至 13 个月中观察到临床改善。[83]Waite LE, Madhok R. Tacrolimus - a potential therapy for polymyositis? Rheumatology (Oxford). 2009;48:858-859.http://rheumatology.oxfordjournals.org/content/48/7/858.longhttp://www.ncbi.nlm.nih.gov/pubmed/19433436?tool=bestpractice.com[84]Shimojima Y, Gono T, Yamamoto K, et al. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol. 2004;23:262-265.http://www.ncbi.nlm.nih.gov/pubmed/15168159?tool=bestpractice.com[85]Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006;34:284-291.http://www.ncbi.nlm.nih.gov/pubmed/16583368?tool=bestpractice.com麦考酚酯对难治性皮肌炎和多发性肌炎的疗效较好;但是,缺乏对照试验。[86]Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65-69.http://archderm.ama-assn.org/cgi/content/full/142/1/65http://www.ncbi.nlm.nih.gov/pubmed/16415388?tool=bestpractice.com[87]Ytterberg SR. Treatment of refractory polymyositis and dermatomyositis. Curr Rheumatol Rep. 2006;8:167-173.http://www.ncbi.nlm.nih.gov/pubmed/16901073?tool=bestpractice.com2 至 3 个月后可观察到麦考酚酯的功效,治疗时间的长度依据患者个人反应而定。
非药物疗法不常用作次选治疗。此外,很少有比较这些治疗的对照试验(如果有的话);而且对其使用顺序尚未形成共识。血浆置换和白细胞分离法已被采用,尽管最近有证据发现它们无效。[88]Dau PC, Bennington JL. Plasmapheresis in childhood dermatomyositis. J Pediatr. 1981;98:237-240.http://www.ncbi.nlm.nih.gov/pubmed/7463219?tool=bestpractice.com[89]Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380-1384.http://www.ncbi.nlm.nih.gov/pubmed/1472183?tool=bestpractice.com据报道,全身照射在少数病例中是有效的。[90]Hubbard WN, Walport MJ, Halnan KE, et al. Remission from polymyositis after total body irradiation. Br Med J (Clin Res Ed). 1982;284:1915-1916.http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1498816&blobtype=pdfhttp://www.ncbi.nlm.nih.gov/pubmed/6805762?tool=bestpractice.com[91]Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve. 1988;11:120-123.http://www.ncbi.nlm.nih.gov/pubmed/3278219?tool=bestpractice.com相反,其他研究发现,全身照射在包涵体肌炎中无效且属于可能会加重病情的因素。[92]Cherin P, Herson S, Coutellier A, et al. Failure of total body irradiation in polymyositis: report of three cases. Br J Rheumatol. 1992;31:282-283.http://www.ncbi.nlm.nih.gov/pubmed/1555046?tool=bestpractice.com[93]Kelly JJ Jr, Madoc-Jones H, Adelman LS, et al. Total body irradiation not effective in inclusion body myositis. Neurology. 1986;36:1264-1266.http://www.ncbi.nlm.nih.gov/pubmed/3748397?tool=bestpractice.com少数皮肌炎与多发性肌炎患者进行了胸腺切除术,并获得了一些改善。[94]Cumming WJ. Thymectomy in refractory dermatomyositis. Muscle Nerve. 1989;12:424.http://www.ncbi.nlm.nih.gov/pubmed/2725570?tool=bestpractice.com
炎性肌病的免疫抑制疗法持续时间尚没有明确的指南,视患者反应而定。通常采取长期、尽可能最低成本和最有效的剂量进行治疗。